Egetis Therapeutics (PDPH.F) Stock Overview
A pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PDPH.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeEgetis Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.64 |
| 52 Week High | SEK 0.64 |
| 52 Week Low | SEK 0.64 |
| Beta | 0.76 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| PDPH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 2.2% |
| 1Y | n/a | 42.0% | 31.1% |
Return vs Industry: Insufficient data to determine how PDPH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how PDPH.F performed against the US Market.
Price Volatility
| PDPH.F volatility | |
|---|---|
| PDPH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PDPH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine PDPH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 42 | Nicklas Westerholm | www.egetis.com |
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) Fundamentals Summary
| PDPH.F fundamental statistics | |
|---|---|
| Market cap | US$322.96m |
| Earnings (TTM) | -US$40.37m |
| Revenue (TTM) | US$6.81m |
Is PDPH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PDPH.F income statement (TTM) | |
|---|---|
| Revenue | SEK 63.10m |
| Cost of Revenue | SEK 54.10m |
| Gross Profit | SEK 9.00m |
| Other Expenses | SEK 383.10m |
| Earnings | -SEK 374.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 21, 2026
| Earnings per share (EPS) | -0.81 |
| Gross Margin | 14.26% |
| Net Profit Margin | -592.87% |
| Debt/Equity Ratio | 28.3% |
How did PDPH.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/11 09:30 |
| End of Day Share Price | 2026/04/28 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Egetis Therapeutics AB (publ) is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrick Langstrom | ABG Sundal Collier Sponsored |
| Erik Hultgård | Carnegie Investment Bank AB |
| Ulrik Trattner | Carnegie Investment Bank AB |